Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper

Wörmann, Bernhard; Bokemeyer, Carsten; Burmeister, Thomas; Köhne, Claus‐Henning; Schwab, Matthias; Arnold, Dirk; Blohmer, Jens‐Uwe; Borner, Markus; Y. Brucker, Sara; Cascorbi, Ingolf; Decker, Thomas; de Wit, Maike; Dietz, Andreas; Einsele, Hermann; Eisterer, Wolfgang; Folprecht, Gunnar; Hilbe, Wolfgang; Hoffmann, Jürgen; Knauf, Wolfgang; Kunzmann, Volker; R. Largiadèr, Carlo; Lorenzen, Sylvie; Lüftner, Diana; Moehler, Markus; M. Nöthen, Markus; Pox, Christian; Reinacher‐Schick, Anke; Scharl, Anton; Schlegelberger, Brigitte; Seufferlein, Thomas; Sinn, Marianne; Stroth, Matthias; Tamm, Ingo; Trümper, Lorenz; Wilhelm, Martin; Wöll, Ewald; Hofheinz, Ralf‐Dieter

doi:10.1159/000510258

Public

Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper

Published in Oncology Research and Treatment • Jan 1, 2020

Authors:

Bernhard Wörmann

Carsten Bokemeyer

Thomas Burmeister

Abstract

BACKGROUND: 5-Fluorouracil (FU) is one of the most commonly used cytostatic drugs in the systemic treatment of cancer. Treatment with FU may cause severe or life-threatening side effects and the treatment-related mortality rate is 0.2-1.0%. SUMMARY: Among other risk factors associated with increased...

Subject

DPYD

Dihydropyrimidine dehydrogenase

Capecitabine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!